Compare Cytokinetics Inc (CYTK) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while iShares 7-10 Year Treasury Bond ETF trades at $89.45 (market cap $41.24B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 4.9× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| CYTK | IEF | |
|---|---|---|
Market Cap | $8.50B | $41.24B |
Volume | 2,395,556 | 9,141,967 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $97.99 |
52-Week Low | $54.76 | $88.92 |
Typical Hold Time | 19 Days | 108 Days |
Enterprise Value | $8.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
IEF trades at $89.11, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend with moving averages overwhelmingly negative, though oscillators suggest potential oversold conditions. Recent dividend distributions of $0.31-$0.33 per share provide income support. The bond ETF faces headwinds from rising Treasury yields and inflation concerns, with market sentiment leaning defensive amid ongoing bond market volatility.
The outlook remains cautious as IEF navigates the highest Treasury yields in decades. While current yields create potential entry points for income-focused investors, persistent inflation and Federal Reserve policy uncertainty pose significant risks. The ETF's defensive positioning may appeal during market turbulence, but further yield increases could pressure prices lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
